Stratos Wealth Partners LTD. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.5% during the ...

Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

When shares of Zimmer Biomet (NYSE:ZBH) moved down to the $105 mark in September, I believed that real value was showing up. Shares sold off despite the projection of mid-single digit sales growth ...

Zimmer Biomet to acquire Paragon 28 for $13/share, totaling $1.2B in enterprise value. Deal expected to close in H1 2025, with potential $1/share CVR based on 2026 sales milestones. Brand New ...

Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm ...

Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Zimmer Biomet provided 2025 guidance of constant currency revenue growth between 3%-5% and adjusted EPS in the range of $8.15 to $8.35. These projections exclude the impact of the Paragon 28 ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported ...

On Tuesday, the company inked a deal to be acquired by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) at around $1.1 billion in equity and $1.2 billion in enterprise value. Zimmer Biomet plans to ...